PFO
RARE icon

Pathstone Family Office’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pathstone Family Office’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-30
Closed -$1K – 919
2020
Q1 		$1K Buy
+30
New +$1.56K ﹤0.01% 729

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Pathstone Family Office's RARE Position: Q2 2020 in Review

Pathstone Family Office sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2020, closing a stake of 30 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in RARE in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 192 funds tracked by Wall St. Rank hold RARE as of Q2 2020.

  • Pathstone Family Office reported no remaining Ultragenyx Pharmaceutical position as of Q2 2020 after selling out during the quarter.
  • Pathstone Family Office sold 30 Ultragenyx Pharmaceutical shares in Q2 2020, an estimated $1K.
  • Pathstone Family Office first reported a position in Ultragenyx Pharmaceutical in Q1 2020 and held it in 1 quarter.
  • Pathstone Family Office's Ultragenyx Pharmaceutical position peaked at $1K in Q1 2020.
  • 192 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2020.

Based on Pathstone Family Office's 13F filing for Q2 2020, filed 14 Aug 2020.